To The Moon
Home
News
TigerAI
Log In
Sign Up
Kelvin988
+Follow
Posts · 61
Posts · 61
Following · 0
Following · 0
Followers · 0
Followers · 0
Kelvin988
Kelvin988
·
2021-07-07
?
Sorry, this post has been deleted
看
3.34K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Kelvin988
Kelvin988
·
2021-07-02
$Exela Technologies, Inc.(XELA)$
no eye see
看
3.15K
回复
Comment
点赞
5
编组 21备份 2
Share
Report
Kelvin988
Kelvin988
·
2021-06-10
Hah
"New Stock News" Keji Pharmaceutical (02171.HK) will introduce 9 fund-raising investors including Eli Lilly next week
内地生物制药公司科济药业公布招股详细,计划发行9,474.7万股,当中10%为本地发售,90%为国际配售,每股招股价介乎29.6至32.8元,集资最多约31.07亿元。每手500股入场费约16,565.26元,联席保荐人为高盛及瑞银。招股期由下周一起至下周四结束,料於6月18日上市。是次招股共引入9名基石投资者,包括礼来亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、广发证券、Dymon Asia、常春藤及南方基金,合共认购约17.85亿元或2.3亿美元等值股份,设6个月禁售期。
"New Stock News" Keji Pharmaceutical (02171.HK) will introduce 9 fund-raising investors including Eli Lilly next week
看
3.06K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Kelvin988
Kelvin988
·
2021-06-10
Kelvin
"New Stock News" rumors that Gushengtang, a chain Chinese medicine clinic in the mainland, plans to list in Hong Kong this year to raise 300-400 million US dollars
据路透旗下《IFR》报道,内地连锁中医诊所固生堂计划今年来港上市,筹3-4亿美元。公司股东包括中国平安 、中国人寿 及斯道(Eight Roads)等。公司在北京、广州、深圳及佛山等地经营34所诊所。据官网介绍,固生堂中医集传统中医医疗、传统中医教学、中医推广等为一体,总部设在广州,平台服务覆盖全国56个城市。(el/u) ~阿思达克财经新闻网址: www.aastocks.com
"New Stock News" rumors that Gushengtang, a chain Chinese medicine clinic in the mainland, plans to list in Hong Kong this year to raise 300-400 million US dollars
看
2.99K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Kelvin988
Kelvin988
·
2021-06-10
Hahahahahaha
看
3.20K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Load more
No followers yet
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586416125812919","uuid":"3586416125812919","gmtCreate":1623322661149,"gmtModify":1623404527384,"name":"Kelvin988","pinyin":"kelvin988","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/25cdf1b8f4e8f392e7110577c7a7fb02","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":2,"tweetSize":61,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":140880505,"gmtCreate":1625646126507,"gmtModify":1703745554271,"author":{"id":"3586416125812919","authorId":"3586416125812919","name":"Kelvin988","avatar":"https://static.tigerbbs.com/25cdf1b8f4e8f392e7110577c7a7fb02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586416125812919","idStr":"3586416125812919"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140880505","repostId":"1158311385","repostType":4,"isVote":1,"tweetType":1,"viewCount":3335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156144381,"gmtCreate":1625205806043,"gmtModify":1703738347588,"author":{"id":"3586416125812919","authorId":"3586416125812919","name":"Kelvin988","avatar":"https://static.tigerbbs.com/25cdf1b8f4e8f392e7110577c7a7fb02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586416125812919","idStr":"3586416125812919"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>no eye see","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>no eye see","text":"$Exela Technologies, Inc.(XELA)$no eye see","images":[{"img":"https://static.tigerbbs.com/518943a749efb46dab3017aa3dcb1edd","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/156144381","isVote":1,"tweetType":1,"viewCount":3151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":183859675,"gmtCreate":1623323433597,"gmtModify":1704200871660,"author":{"id":"3586416125812919","authorId":"3586416125812919","name":"Kelvin988","avatar":"https://static.tigerbbs.com/25cdf1b8f4e8f392e7110577c7a7fb02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586416125812919","idStr":"3586416125812919"},"themes":[],"htmlText":"Hah ","listText":"Hah ","text":"Hah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183859675","repostId":"2140408437","repostType":4,"repost":{"id":"2140408437","kind":"news","pubTimestamp":1622800499,"share":"https://ttm.financial/m/news/2140408437?lang=en_US&edition=fundamental","pubTime":"2021-06-04 17:54","market":"us","language":"zh","title":"\"New Stock News\" Keji Pharmaceutical (02171.HK) will introduce 9 fund-raising investors including Eli Lilly next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2140408437","media":"AAFN","summary":"内地生物制药公司科济药业公布招股详细,计划发行9,474.7万股,当中10%为本地发售,90%为国际配售,每股招股价介乎29.6至32.8元,集资最多约31.07亿元。每手500股入场费约16,565.26元,联席保荐人为高盛及瑞银。招股期由下周一起至下周四结束,料於6月18日上市。是次招股共引入9名基石投资者,包括礼来亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、广发证券、Dymon Asia、常春藤及南方基金,合共认购约17.85亿元或2.3亿美元等值股份,设6个月禁售期。","content":"<p><html><body>Keji Pharmaceutical (02171.HK), a mainland biopharmaceutical company, announced the details of its offering. It plans to issue 94.747 million shares, of which 10% will be offered locally and 90% will be offered internationally. The offering price per share ranges from 29.6 to 32.8 yuan, raising a maximum of about 3.107 billion yuan. The admission fee for each board lot of 500 shares is approximately $16,565.26 and the joint sponsors are<a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a>And<a href=\"https://laohu8.com/S/UBS\">UBS</a>。 The IPO period will start from next Monday (7th) to next Thursday (10th), and it is expected to be listed on June 18th. A total of 9 cornerstone investors were introduced into the IPO, including<a href=\"https://laohu8.com/S/LLY\">Lilly</a>Asia Fund, Xinhua Life Insurance, CloudAlpha, Ruiyuan, WT Fund,<a href=\"https://laohu8.com/S/000776\">GF Securities</a>Dymon Asia, Ivy and Southern Fund, subscribed for approximately $1,785 million or US$230 million equivalent shares in aggregate, with a six-month lock-up period. Xie Lan, senior vice president of finance, said that because the company has not yet commercialized its products, it has recorded operating losses in the past few years. Last year's loss reached 1.064 billion yuan. It is expected to submit a new drug listing application in China for the core product CT053 in the first half of next year. Asked about hot new stocks<a href=\"https://laohu8.com/S/06699\">Angel of the Times</a>(06699.HK) During the collision period, Li Zonghai, chairman of the board of directors, CEO and chief scientific officer, said that each company has its own characteristics, and investors also have different focuses. He also pointed out that the products under development have shown efficacy and safety in clinical trials, and I believe it will be recognized by the market. (gc/A) ~ ASTACK Financial News Website: www.aastocks.com</p><p></body></html></p>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>\"New Stock News\" Keji Pharmaceutical (02171.HK) will introduce 9 fund-raising investors including Eli Lilly next week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n\"New Stock News\" Keji Pharmaceutical (02171.HK) will introduce 9 fund-raising investors including Eli Lilly next week\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">AAFN</strong><span class=\"h-time small\">2021-06-04 17:54</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>Keji Pharmaceutical (02171.HK), a mainland biopharmaceutical company, announced the details of its offering. It plans to issue 94.747 million shares, of which 10% will be offered locally and 90% will be offered internationally. The offering price per share ranges from 29.6 to 32.8 yuan, raising a maximum of about 3.107 billion yuan. The admission fee for each board lot of 500 shares is approximately $16,565.26 and the joint sponsors are<a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a>And<a href=\"https://laohu8.com/S/UBS\">UBS</a>。 The IPO period will start from next Monday (7th) to next Thursday (10th), and it is expected to be listed on June 18th. A total of 9 cornerstone investors were introduced into the IPO, including<a href=\"https://laohu8.com/S/LLY\">Lilly</a>Asia Fund, Xinhua Life Insurance, CloudAlpha, Ruiyuan, WT Fund,<a href=\"https://laohu8.com/S/000776\">GF Securities</a>Dymon Asia, Ivy and Southern Fund, subscribed for approximately $1,785 million or US$230 million equivalent shares in aggregate, with a six-month lock-up period. Xie Lan, senior vice president of finance, said that because the company has not yet commercialized its products, it has recorded operating losses in the past few years. Last year's loss reached 1.064 billion yuan. It is expected to submit a new drug listing application in China for the core product CT053 in the first half of next year. Asked about hot new stocks<a href=\"https://laohu8.com/S/06699\">Angel of the Times</a>(06699.HK) During the collision period, Li Zonghai, chairman of the board of directors, CEO and chief scientific officer, said that each company has its own characteristics, and investors also have different focuses. He also pointed out that the products under development have shown efficacy and safety in clinical trials, and I believe it will be recognized by the market. (gc/A) ~ ASTACK Financial News Website: www.aastocks.com</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source:<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1103479&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">AAFN</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8484c32aa045a32d4ca87a47aef4e825","relate_stocks":{"02171":"科济药业-B"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1103479&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140408437","content_text":"内地生物制药公司科济药业(02171.HK)公布招股详细,计划发行9,474.7万股,当中10%为本地发售,90%为国际配售,每股招股价介乎29.6至32.8元,集资最多约31.07亿元。每手500股入场费约16,565.26元,联席保荐人为高盛及瑞银。招股期由下周一(7日)起至下周四(10日)结束,料於6月18日上市。是次招股共引入9名基石投资者,包括礼来亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、广发证券、Dymon Asia、常春藤及南方基金,合共认购约17.85亿元或2.3亿美元等值股份,设6个月禁售期。财务高级副总裁谢岚表示,由於公司尚未有产品商业化,因此过往几年录得经营亏损,去年度亏损达10.64亿元人民币,料於明年上半年就核心产品CT053提交中国新药上市申请。问到与热门新股时代天使(06699.HK)撞期,董事会主席、首席执行官兼首席科学官李宗海称,每家公司都有特点,投资者亦有不同关注重点,又指在研产品於临床实验中显示出有疗效及安全性,相信会得到市场认可。(gc/a)~阿思达克财经新闻网址: www.aastocks.com","news_type":1,"symbols_score_info":{"02171":0.9}},"isVote":1,"tweetType":1,"viewCount":3055,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183850225,"gmtCreate":1623323383167,"gmtModify":1704200870680,"author":{"id":"3586416125812919","authorId":"3586416125812919","name":"Kelvin988","avatar":"https://static.tigerbbs.com/25cdf1b8f4e8f392e7110577c7a7fb02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586416125812919","idStr":"3586416125812919"},"themes":[],"htmlText":"Kelvin ","listText":"Kelvin ","text":"Kelvin","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183850225","repostId":"2141651312","repostType":4,"repost":{"id":"2141651312","kind":"news","pubTimestamp":1623146294,"share":"https://ttm.financial/m/news/2141651312?lang=en_US&edition=fundamental","pubTime":"2021-06-08 17:58","market":"us","language":"zh","title":"\"New Stock News\" rumors that Gushengtang, a chain Chinese medicine clinic in the mainland, plans to list in Hong Kong this year to raise 300-400 million US dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=2141651312","media":"AAFN","summary":"据路透旗下《IFR》报道,内地连锁中医诊所固生堂计划今年来港上市,筹3-4亿美元。公司股东包括中国平安 、中国人寿 及斯道(Eight Roads)等。公司在北京、广州、深圳及佛山等地经营34所诊所。据官网介绍,固生堂中医集传统中医医疗、传统中医教学、中医推广等为一体,总部设在广州,平台服务覆盖全国56个城市。(el/u) ~阿思达克财经新闻网址: www.aastocks.com","content":"<p><html><body>According to Reuters's IFR, Gushengtang, a Chinese medicine clinic chain in the mainland, plans to list in Hong Kong this year, raising $300-400 million. Shareholders of the Company include<a href=\"https://laohu8.com/S/601318\">Ping An of China</a>、<a href=\"https://laohu8.com/S/LFC\">China Life</a>And Eight Roads, etc. The company operates 34 clinics in Beijing, Guangzhou, Shenzhen and Foshan. According to official website, Gushengtang Traditional Chinese Medicine integrates traditional Chinese medicine medical treatment, traditional Chinese medicine teaching and traditional Chinese medicine promotion. It is headquartered in Guangzhou, and its platform services cover 56 cities across the country. (el/u) ~ ASTACK Financial News Website: www.aastocks.com</p><p></body></html></p>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>\"New Stock News\" rumors that Gushengtang, a chain Chinese medicine clinic in the mainland, plans to list in Hong Kong this year to raise 300-400 million US dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n\"New Stock News\" rumors that Gushengtang, a chain Chinese medicine clinic in the mainland, plans to list in Hong Kong this year to raise 300-400 million US dollars\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">AAFN</strong><span class=\"h-time small\">2021-06-08 17:58</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>According to Reuters's IFR, Gushengtang, a Chinese medicine clinic chain in the mainland, plans to list in Hong Kong this year, raising $300-400 million. Shareholders of the Company include<a href=\"https://laohu8.com/S/601318\">Ping An of China</a>、<a href=\"https://laohu8.com/S/LFC\">China Life</a>And Eight Roads, etc. The company operates 34 clinics in Beijing, Guangzhou, Shenzhen and Foshan. According to official website, Gushengtang Traditional Chinese Medicine integrates traditional Chinese medicine medical treatment, traditional Chinese medicine teaching and traditional Chinese medicine promotion. It is headquartered in Guangzhou, and its platform services cover 56 cities across the country. (el/u) ~ ASTACK Financial News Website: www.aastocks.com</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source:<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1104136&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">AAFN</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","relate_stocks":{"02628":"中国人寿","00388":"香港交易所","02318":"中国平安","02273":"固生堂"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1104136&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2141651312","content_text":"据路透旗下《IFR》报道,内地连锁中医诊所固生堂计划今年来港上市,筹3-4亿美元。公司股东包括中国平安 、中国人寿 及斯道(Eight Roads)等。公司在北京、广州、深圳及佛山等地经营34所诊所。据官网介绍,固生堂中医集传统中医医疗、传统中医教学、中医推广等为一体,总部设在广州,平台服务覆盖全国56个城市。(el/u) ~阿思达克财经新闻网址: www.aastocks.com","news_type":1,"symbols_score_info":{"02273":0.9,"02628":0.9,"02318":0.6,"00388":0.6}},"isVote":1,"tweetType":1,"viewCount":2985,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183824477,"gmtCreate":1623323265999,"gmtModify":1704200868900,"author":{"id":"3586416125812919","authorId":"3586416125812919","name":"Kelvin988","avatar":"https://static.tigerbbs.com/25cdf1b8f4e8f392e7110577c7a7fb02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586416125812919","idStr":"3586416125812919"},"themes":[],"htmlText":"Hahahahahaha","listText":"Hahahahahaha","text":"Hahahahahaha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183824477","isVote":1,"tweetType":1,"viewCount":3201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}